Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory

Figure 2

Individual TB treatment patterns and vital status at 24 months after TB diagnosis for 30 TB/HIV patients from Minsk, Belarus according to the results of Mycobacterium tuberculosis (Mtb) drug-susceptibility testing performed at two different laboratories (Belarus vs. Denmark). Abbreviations: Am = amikacin; Amx-Clv = amoxicillin-clavulanic acid; Cm = capreomycin; Cs = cycloserine; E = ethambutol; Eto = ethionamide; H = isoniazid; Km = kanamycin; Lfx = levofloxacin; Lzd = linezolid; Mfx = moxifloxacin; Ofx = ofloxacin; PAS = p-aminosalicylic acid; Pto = prothionamide; R = rifampicin; S = streptomycin; Z = pyrazinamide; PID = patient’s identification number. In Minsk, DST was performed at the Republican Scientific and Practical Center for Pulmonology and TB, Minsk, Belarus. In Copenhagen, DST was performed at the WHO TB Supranational Reference Laboratory, Copenhagen, Denmark. Number in front of drug combination means number of months the drug combination was used. A drug was included in the analysis, if it was used for >15 days. Green = Mtb was sensitive to a drug. Red = Mtb was resistant to a drug. Orange = Mtb was sensitive to a drug by DST analysis in Minsk and resistant in Copenhagen. Blue = Mtb was resistant by DST analysis in Minsk and sensitive in Copenhagen. In case of discrepancies between phenotypic and genotypic tests within laboratory in Copenhagen, the worst result (i.e. resistance) was considered. DS = Drug sensitive TB; Mtb sensitive to all first-line anti-TB drugs. Mono-resistant TB = Mtb resistant to one first-line anti-TB drug only. MDR-TB = multidrug resistant TB; Mtb resistant to at least both isoniazid and rifampicin. preXDR-TB = preextensive drug resistance; Mtb resistant to isoniazid and rifampicin and either to any fluoroquinolone or a second-line injectable agent but not to both. XDR-TB = extensive drug resistance; Mtb resistant to isoniazid and rifampicin and to any fluoroquinolone and to at least one of three second-line injectable drugs.